三叶草生物任命Nicholas Jackson为全球研发与战略联盟总裁

Core Insights - The company has appointed Nicholas Jackson as the President of Global R&D and Strategic Alliances [1] - Nicholas Jackson will work closely with CEO Liang Guo to accelerate the development of the company's combined vaccine candidate RSV+hMPV±PIV3 [1] Company Developments - The appointment of Nicholas Jackson is aimed at enhancing the company's research and development capabilities [1] - The focus on the RSV+hMPV±PIV3 vaccine candidate indicates the company's commitment to addressing respiratory viral infections [1]